Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

896.53 +33.67 (+3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
 
Via Benzinga
Topics Initial Public Offering
4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
Via AB Newswire
Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off'
Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending. 
Via Benzinga
Eli Lilly (LLY): 3 Reasons We Love This Stock
Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period. 
Via StockStory
Topics Stocks Supply Chain
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Novo Nordisk Shares Tumble Amid Sweeping Board Overhaul
Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move... 
Via MarketMinute
Topics Economy Government Intellectual Property
Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager
Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager 
Via The Motley Fool
3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report
The rapid growth rates of recent years aren't guaranteed to continue. 
Via The Motley Fool
Topics Intellectual Property
Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains. 
Via MarketBeat
Topics Artificial Intelligence
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
Don't try to catch a falling surgical knife. 
Via The Motley Fool
Topics Government
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
The tides continue to change in Eli Lilly's favor in the GLP-1 space. 
Via The Motley Fool
3 Overrated Stocks That Fall Short
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
Here's How Much $100 Invested In Eli Lilly 20 Years Ago Would Be Worth Today
 
Via Benzinga
Jim Cramer's Crystal Ball: Unpacking the Market's Top 10 Drivers for a Pivotal Monday
As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market.... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients. 
Via Investor's Business Daily
Topics Government
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
3 Hyped Up Stocks We Think Twice About
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fears
Via The Motley Fool
Topics Regulatory Compliance
Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent Filing
Via The Motley Fool
Topics Regulatory Compliance
Large Wealth Advisor Trims Exposure to Red-Hot Digital Advertising Stock
Via The Motley Fool
Topics Regulatory Compliance
Got $5,000? 2 Stocks to Buy Now and Hold for the Long Term
These two high-quality stocks can deliver impressive returns in the long run. 
Via The Motley Fool
Topics Artificial Intelligence
'No Place Is Risk-Free Until The World Is Polio-Free:' Bill Gates Urges Global Action To Close Deadly Immunity Gaps
Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps. 
Via Benzinga
Benzinga Bulls And Bears: Stellantis, Papa John's, Oklo — And Trade Tensions Shake Chip Stocks
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics World Trade
Had You Invested $10,000 in the Vanguard S&P 500 Growth ETF 10 Years Ago, Here's How Much You'd Have Today
The Vanguard S&P 500 Growth ETF typically outperforms the S&P 500 over the long term. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure. 
Via Benzinga
Topics ETFs Government
Uncover the latest developments among S&P500 stocks in today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but... 
Via Benzinga
Topics Government Intellectual Property
Why Eli Lilly (LLY) Stock Is Down Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s... 
Via StockStory
Topics Economy Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.